David Morris, MD, FACS

Explore the complexities of treatment protocols for metastatic hormone-sensitive patients, focusing on therapy cessation and re-initiation strategies.

Affordability and Accessibility of Therapies in mCSPC Care

Experts discuss evolving treatment strategies for metastatic castration-resistant prostate cancer, emphasizing personalized therapy and innovative options.

Experts discuss evolving treatment strategies for metastatic castration-resistant prostate cancer, emphasizing personalized therapy and innovative options.

Healthcare professionals discuss patient selection, treatment strategies, and compliance tools for managing advanced prostate cancer effectively.

Experts discuss the importance of genetic testing in managing aggressive prostate cancer, emphasizing early testing and actionable mutations for treatment decisions.

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

Healthcare professionals discuss the importance of patient counseling on treatment options, emphasizing the balance between efficacy and quality of life.

Identifying the Ideal Patient for Doublet versus triplet in mCSPC

Explore the latest long-term data on abiraterone and enzalutamide, revealing survival benefits and safety insights for prostate cancer treatments.

Explore the evolving landscape of prostate cancer treatments, focusing on efficacy, tolerability, and the nuances of various therapies.

Experts discuss the future of metastatic cancer treatment, focusing on risk stratification, personalized therapies, and the balance between intensification and de-escalation.

Healthcare professionals discuss the importance of patient characteristics and comorbidities in selecting effective and tolerable treatments.

Healthcare professionals discuss the importance of patient characteristics and comorbidities in selecting effective and tolerable treatments.

Mechanisms of Action and Differentiation Among ARPI Therapies in mCSPC

Current Treatment Landscape and Guideline Recommendations in mCSPC

Explore strategies for seamless coordination between urologists and medical oncologists to ensure uninterrupted, patient-focused care in prostate cancer treatment.

Explore the coordinated approach between urologists and medical oncologists to ensure smooth transitions and ongoing care for patients receiving combination therapies in prostate cancer treatment.

Join experts David Morris, MD, FACS, and Benjamin Garmezy, MD, as they discuss the barriers and considerations in prescribing triplet therapy, offering insight into its benefits and how collaborative care between urologists and medical oncologists ensures a seamless patient journey.

Discover considerations for doublet or triplet therapy in advanced prostate cancer, analyzing the benefits and manageable added toxicity, as discussed by renowned experts in the field.

Join key opinion leaders as they analyze the evolving landscape of metastatic HSPC, delving into the advantages and key factors to consider with triplet combination therapies, encompassing chemotherapy and ARPI agents.

Explore the evolving landscape of hormone therapies in prostate cancer treatment with insights from expert physicians as they delve into the latest options, indications, and their impact on patient care.

A brief review of the evolving realm of prostate cancer care centered on the significance of identifying high-risk cases and addressing the complexities of risk stratification and prognosis.

A discussion surrounding the changing landscape of early-stage prostate cancer screening and rise in metastatic disease cases, focusing on the importance of timely intervention and patient-focused care.

Delve into the strategic process of selecting ideal partners in cancer care as key opinion leaders share insights on building trust, effective communication, and optimizing patient outcomes through collaborative decision making.

Explore how David Morris, MD, FACS, and Benjamin Garmezy, MD, join forces to enhance patient outcomes in advanced prostate cancer through their innovative and collaborative precision medicine strategies.

Experts summarize how the use of PSMA-PET imaging has impacted the field to date and share their hopes for the future.

The panel discusses the possibility of PSMA-PET becoming the standard-of-care imaging modality for prostate cancer, which may obviate the need for conventional imaging and bone scans, and then touches on the increasing availability of PSMA-targeted radiotherapies.

Drs Cookson and Sellinger discuss the remaining unmet needs in imaging for patients with prostate cancer.

The panel shares their perspectives on the transition to virtual multidisciplinary tumor boards for patients with prostate cancer after the COVID-19 pandemic.